Dr. Quick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4101 22nd Pl
Lubbock, TX 79410Phone+1 806-725-8000Fax+1 806-723-6532
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1985 - 1988
Texas A&M College of Medicine-Scott and White Medical Center (Temple)Residency, Internal Medicine, 1982 - 1985
Baylor College of MedicineClass of 1982
Certifications & Licensure
NM State Medical License 2005 - 2027
TX State Medical License 1983 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
- Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer Start of enrollment: 2012 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsPomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-rel...Nizar J Bahlis, David S Siegel, Gary J Schiller, Christy Samaras, Michael Sebag
Leukemia & Lymphoma. 2022-06-01 - 1 citationsPhase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.Alexis C Boulter, Barry J Maurer, Meredith Pogue, Min H Kang, Hwangeui Cho
Cancer Chemotherapy and Pharmacology. 2023-08-01 - 57 citationsPomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentDavid S. Siegel, Gary J. Schiller, Christy J. Samaras, Michael Sebag, Jesus G. Berdeja
Leukemia. 2020-05-06
Abstracts/Posters
- Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...Donald P. Quick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled TrialsDonald P. Quick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with DaratumumabDonald P. Quick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
